The newest approved treatment for sleep apnea is Zepbound (tirzepatide). In December 2024 it became the first prescription medication the FDA approved for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Other recent additions are the next-generation Inspire V implant (approved August 2024) and the Genio bilateral nerve stimulator (approved August 2025). A nightly pill, AD109, is under FDA review with a decision target of February 28, 2027. CPAP is still the first-line treatment for most people.
Key Takeaways
- Zepbound (weekly injection) is approved for moderate to severe OSA in adults with obesity, alongside diet and exercise.
- Hypoglossal nerve stimulation (Inspire, Inspire V, Genio) is an implant option for some people who can't use CPAP.
- AD109, an oral pill, isn't approved yet. The FDA's target decision date is February 28, 2027.
- eXciteOSA is a daytime tongue-stimulation device for snoring and mild OSA.
- Newer doesn't automatically mean better. The right treatment depends on your sleep study results, anatomy, weight, and preferences.

1. Zepbound (Tirzepatide): The First Drug for Sleep Apnea
On December 20, 2024, the FDA approved Zepbound for "the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity," to be used with a reduced-calorie diet and increased physical activity. Tirzepatide is a once-weekly injection that activates GLP-1 and GIP hormone receptors, which reduces appetite and leads to weight loss. Excess weight is a major driver of OSA, and weight loss lowers the number of breathing interruptions.
The evidence: The FDA based the approval on two 52-week randomized, placebo-controlled trials in 469 adults with obesity and moderate to severe OSA. One trial included people using positive airway pressure (PAP), and the other included people who couldn't or wouldn't use PAP. Zepbound significantly reduced the apnea-hypopnea index (AHI, breathing events per hour) compared with placebo. More participants reached remission or mild OSA.
Who it's for: Adults with obesity and moderate to severe OSA. It isn't approved for OSA in people without obesity.
Side effects and cautions: The most common side effects are nausea, diarrhea, vomiting, and constipation. It shouldn't be used by people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your surgical team you take it before any procedure with anesthesia.
Zepbound doesn't replace CPAP for everyone. Many people use both, especially while losing weight. Ask your doctor before stopping CPAP.
2. Hypoglossal Nerve Stimulation: Inspire, Inspire V, and Genio
Hypoglossal nerve stimulation (HGNS) uses a small implanted device that stimulates the nerve controlling the tongue, moving the tongue forward during sleep so it doesn't block the airway. You turn it on at bedtime with a remote.
- Inspire was first approved in 2014. In 2023, the FDA expanded its labeling to people with an AHI of 15 to 100 and raised the body mass index (BMI) limit to 40. It's indicated for adults 22 and older with moderate to severe OSA who can't use or tolerate CPAP, with separate criteria for ages 18–21 and for teens 13–18 with Down syndrome.
- Inspire V, the next-generation system, was approved in August 2024 and rolled out in the U.S. through 2025. It uses an updated neurostimulator and Bluetooth-enabled remote and programmer.
- Genio (Nyxoah) was approved by the FDA in August 2025 for moderate to severe OSA (AHI 15–65). It stimulates both sides of the tongue-control nerve and uses an external, wearable power unit.
Before any HGNS implant, candidates typically need a sleep study and a drug-induced sleep endoscopy to check the pattern of airway collapse. Learn more in our guide to Inspire for sleep apnea.
3. AD109: A Nightly Pill Under FDA Review
AD109, developed by Apnimed, combines aroxybutynin (2.3 mg) and atomoxetine (75 mg) in one pill taken at bedtime. It's designed to keep upper-airway muscles more active during sleep. In two phase 3 trials (SynAIRgy and LunAIRo), it significantly reduced AHI and improved oxygen measures compared with placebo. The most common side effects were dry mouth, insomnia, and nausea.
In July 2026 the FDA accepted Apnimed's new drug application and set a target action date of February 28, 2027. As of October 2026 it is not approved, and approval isn't guaranteed.
4. eXciteOSA: Daytime Tongue Training
eXciteOSA received FDA De Novo authorization in February 2021 as the first device used while awake to reduce snoring and mild OSA. You hold a mouthpiece with electrodes on your tongue for 20 minutes a day for six weeks, then once a week, to strengthen the tongue muscles. It's for adults with snoring or mild OSA (AHI under 15), not moderate or severe disease. It isn't suitable for people with pacemakers, braces, or metal dental work.
5. Improvements to Established Treatments
CPAP and auto-adjusting PAP
CPAP remains the first-line treatment for most adults with moderate to severe OSA. Modern auto-adjusting machines (APAP) change pressure through the night, and newer masks, humidifiers, and quieter motors have made therapy easier to tolerate. Compare current models in our best CPAP machines guide, and see CPAP settings explained.
Oral appliances
Custom mandibular advancement devices from a dentist hold the lower jaw forward to keep the airway open. They're an option for mild to moderate OSA or for people who can't tolerate CPAP. Learn more about dental alternatives to CPAP.
Positional therapy and lifestyle changes
For people whose apnea happens mainly on their back, positional devices can help. Weight loss, avoiding alcohol and sedatives near bedtime, and treating nasal congestion all improve OSA. See the best sleep position for sleep apnea and how to sleep with sleep apnea without CPAP.
Comparing the Newest Sleep Apnea Treatments
| Treatment | Type | Status (Oct 2026) | Best suited for |
|---|---|---|---|
| Zepbound (tirzepatide) | Weekly injection | FDA-approved Dec 2024 | Moderate to severe OSA in adults with obesity |
| Inspire / Inspire V | Implanted nerve stimulator | FDA-approved (Inspire V: Aug 2024) | Moderate to severe OSA, can't use CPAP, meets anatomy criteria |
| Genio | Implanted bilateral nerve stimulator | FDA-approved Aug 2025 | Moderate to severe OSA (AHI 15–65), can't use CPAP |
| AD109 | Nightly pill | Under FDA review, decision target Feb 28, 2027 | Not yet available |
| eXciteOSA | Daytime tongue stimulation | FDA De Novo authorization 2021 | Snoring and mild OSA |
| CPAP / APAP | Machine and mask | Standard first-line therapy | Most adults with moderate to severe OSA |
Which Treatment Is Right for You?
Start with a proper diagnosis. A home sleep apnea test or in-lab study measures your AHI and oxygen levels, which determine which options fit. Then talk with a sleep specialist about:
- How severe your OSA is, and whether it's obstructive or central sleep apnea (which these treatments mostly don't address)
- Your weight and other health conditions
- Whether you've tried CPAP and what made it hard
- Insurance coverage, which varies widely for implants and newer drugs
See a doctor promptly if you have loud snoring with breathing pauses, gasping, or heavy daytime sleepiness. Untreated OSA raises the risk of high blood pressure, heart disease, and stroke. Read our overview of the benefits of treating sleep apnea.
This article is for general information and is not a substitute for medical advice. Treatment availability and approvals are current as of October 2026.
Frequently Asked Questions
What is the newest treatment for sleep apnea in 2026?
The newest FDA-approved options are Zepbound (tirzepatide), approved in December 2024 as the first medication for moderate to severe OSA in adults with obesity, and the Genio nerve stimulator, approved in August 2025. A pill called AD109 is under FDA review, with a decision expected by February 28, 2027.
Is there a pill for sleep apnea?
Not yet. AD109, a nightly pill combining aroxybutynin and atomoxetine, showed positive results in two phase 3 trials and is under FDA review, with a target decision date of February 28, 2027. Zepbound, the only approved OSA medication, is a weekly injection.
Can Zepbound replace a CPAP machine?
For some people, weight loss on Zepbound reduces sleep apnea enough that CPAP is no longer needed. But that should be confirmed with a repeat sleep study. Many people use both during treatment. Don't stop CPAP without talking to your doctor.
Who qualifies for the Inspire implant?
Generally, adults with moderate to severe obstructive sleep apnea (AHI 15–100) who can't use or tolerate CPAP, and who have a suitable airway collapse pattern on drug-induced sleep endoscopy. A BMI of 40 or lower is recommended. Your sleep surgeon confirms eligibility.
What is the best alternative to CPAP?
It depends on the person. Oral appliances work well for many people with mild to moderate OSA. Hypoglossal nerve stimulation is an option for moderate to severe OSA when CPAP fails. Zepbound may help adults with obesity. Weight loss and positional therapy help in selected cases.
Is there a cure for sleep apnea?
Some people can eliminate obstructive sleep apnea, for example through significant weight loss or surgery that corrects an anatomical cause, such as removing large tonsils. For most adults, OSA is a chronic condition that's managed rather than cured. See our article on whether sleep apnea can be cured.
Sources
- FDA — FDA Approves First Medication for Obstructive Sleep Apnea (Dec. 20, 2024)
- FDA — Inspire Upper Airway Stimulation (P130008/S090) expanded indication
- AASM — FDA approves next-generation Inspire V therapy system
- Nyxoah — FDA approval of the Genio system (Aug. 2025)
- Apnimed — FDA acceptance of the AD109 new drug application (July 2026)
- FDA (via BioSpace) — FDA authorizes marketing of eXciteOSA (Feb. 2021)
- NHLBI (NIH) — Sleep Apnea Treatment
